
Profitability, historical returns, and peer comparisons.
According to Puma Biotechnology, Inc.’s latest financial reports and current stock price. The company's current ROE is 20.85%. This represents a change of 297.70% compared to the average of 5.24% of the last 4 quarters.
The mean historical ROE of Puma Biotechnology, Inc. over the last ten years is 85.26%. The current 20.85% ROE has changed -75.55% with respect to the historical average. Over the past ten years (40 quarters), PBYI's ROE was at its highest in in the September 2020 quarter at 6.95%. The ROE was at its lowest in in the March 2020 quarter at -180.58%.
Average
85.26%
Median
11.94%
Minimum
-547.84%
Maximum
1.19%
Discovering the peaks and valleys of Puma Biotechnology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 436.39%
Maximum Annual ROE = 1.19%
Minimum Annual Increase = -332.89%
Minimum Annual ROE = -547.84%
| Year | ROE | Change |
|---|---|---|
| 2025 | 23.87% | -27.37% |
| 2024 | 32.87% | -18.65% |
| 2023 | 40.40% | 436.39% |
| 2022 | 0.01% | -100.00% |
| 2021 | 1.19% | 18.11% |
| 2020 | 1.01% | -332.89% |
| 2019 | -432.89% | 30.73% |
| 2018 | -331.14% | -39.56% |
| 2017 | -547.84% | 316.44% |
| 2016 | -131.55% | 13.25% |
The current ROE of Puma Biotechnology, Inc. (PBYI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
32.38%
5-year avg
257.58%
10-year avg
85.26%
Puma Biotechnology, Inc.’s ROE is greater than Verastem, Inc. (-467.49%), greater than Black Diamond Therapeutics, Inc. (-38.80%), greater than ArriVent BioPharma, Inc. (-50.26%), less than Oncolytics Biotech Inc. (1.02%), greater than NovaBridge Biosciences (-1.45%), greater than ORIC Pharmaceuticals, Inc. (-35.35%), greater than Nuvation Bio Inc. (-49.73%), greater than Tango Therapeutics, Inc. (-25.74%), greater than MacroGenics, Inc. (-31.27%), greater than Cardiff Oncology, Inc. (-103.08%),
| Company | ROE | Market cap |
|---|---|---|
| -467.49% | $892.05M | |
| -38.80% | $108.87M | |
| -50.26% | $665.16M | |
| 1.02% | $42.63M | |
| -1.45% | $116.42M | |
| -35.35% | $968.12M | |
| -49.73% | $1.66B | |
| -25.74% | $3.91B | |
| -31.27% | $147.15M | |
| -103.08% | $67.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Puma Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Puma Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Puma Biotechnology, Inc.'s ROE?
How is the ROE calculated for Puma Biotechnology, Inc. (PBYI)?
What is the highest ROE for Puma Biotechnology, Inc. (PBYI)?
What is the 3-year average ROE for Puma Biotechnology, Inc. (PBYI)?
What is the 5-year average ROE for Puma Biotechnology, Inc. (PBYI)?
How does the current ROE for Puma Biotechnology, Inc. (PBYI) compare to its historical average?